* Bio-Technology General Corp., of Iselin, N.J., completed aprivate placement of 5.1 million shares, raising $9 million. Thecompany said it has $18.5 million in cash and 43 million sharesoutstanding.* Bio-Pharm Drug Delivery Services, a division of Blue Bell, Pa.-based IBAH Inc., has extended an agreement with Eli Lilly & Co.,of Indianapolis, into the first quarter of 1995. The collaborationinvolves use of Bio-Pharm's Lipid Dispersal Systems indevelopment of Lilly's compounds for treatment of infectiousdiseases and cardiovascular disorders.* Biomira Inc., of Edmonton, Canada, has received FDA approvalto begin Phase II trials of its Theratope vaccine for late stage breast,ovarian and colorectal cancers. The company released preliminaryresults of Canadian Phase II trials of Theratope last month. (SeeBioWorld Today, Sept. 22, 1994, p. 2.)* Zonagen Inc., of The Woodlands, Texas, has acquired FertilityTechnologies Inc., of Natick, Mass., Fertility is a private companyspecializing in products to diagnose and treat reproductivedisorders.* Liposome Technologies Inc., of Menlo Park, Calif., has receivedapproval from Ireland's Department of Health to market anantifungal compound, Amphocil. The company began marketingthe drug in the U.K. in May.* Matrix Pharmaceutical Inc., of Menlo Park, Calif., has releasedpreclinical trial results demonstrating that its AccuSite injectable gelsuppressed latent viral infection and reduced the size of papillomasin rabbits infected with Shope papilloma. The Shope rabbit model isused to evaluate new treatments for genital warts. The companysaid the preclinical findings complement its Phase III clinical trialsof AccuSite for genital warts.* Macronex Inc., of Morrisville, N.C., said preclinical studies of itslead compound, MNX160, revealed the drug prevented death inmice injected with toxins. MNX160 is a designed to inhibit theproduction of tumor necrosis factor-a.* Cel-Sci Corp., of Alexandria, Va., received a $1 million loan fromSilicon Valley East in Wellesley, Mass. The funds are being usedfor Cel-Sci's new facility, called PRA Laboratories, in Baltimore.The laboratory is designed to provide validated testing to quantifycytokines.* Paracelsian Inc., of Ithaca, N.Y., signed a letter of intent to acquireIthaca-based Pacific Liaisons, a partnership that deals inbiologically active drugs, natural products and foods from the FarEast.* LifeCell Corp., of The Woodlands, Texas, formed a collaborativeagreement with Peter Elias at the Veterans Affairs Medical Centerin San Francisco, focused on developing an in vitro test systemusing keratinocyte-cultured AlloDerm, which is processed fromhuman donor skin.* Neogen Corp., of Lansing, Mich., has received two U.S.Department of Agriculture contracts to develop tests for bacterialcontamination of meat and poultry.* ImmunoTherapeutics Inc., of Fargo, N.D., has implemented ashareholder's protection rights plan to guard against an unwantedtakeover of the company.* Allelix Biopharmaceuticals Inc., of Toronto, said two Phase Itrials of ALX1-11, a recombinant human parathyroid hormone, forosteoporosis involved 72 volunteers and revealed that healthy,postmenopausal women showed no risk of frank hypercalcemia atlower doses in single treatments for seven days.* Cell Therapeutics Inc., of Seattle, reported that Lisofylline, thecompany's oncology drug, accelerated recovery of red and whiteblood cells and platelets in animals receiving high doses ofchemotherapy.* Cantab Pharmaceuticals plc, of Cambridge, England, has opened afacility to manufacture viral- and protein-based products forpreclinical and early stage clinical trials. The plant's activities in1995 will include production of Cantab's TA-GW drug candidatefor genital warts and TA-HPV for cervical cancer.
(c) 1997 American Health Consultants. All rights reserved.